A retrospective, postmarketing study demonstrates higher incidence of joint and bone pain, neutropenia with certain filgrastim biosimilars, compared with Neupogen.
Editor's Note: Since publication of this article, the findings in the study by Rastogi S et al referenced below have been criticized as having been based on poor scientific methodology. Reliance upon data from the VigiBase adverse event database of the World Health Organisation, which is not intended for the testing of medical hypotheses, is one of the criticisms leveled against this study. The Center for Biosimilars® is preparing a follow-up article on this issue.
A new study has associated a higher incidence of certain adverse events with the filgrastim biosimilars, Zarzio, Grasin, Nivestim, and Tevagrastim compared with the reference product Neupogen.
These biosimilar products are marketed outside the United States under these brands and have US equivalents.
Filgrastim was originally approved in 1991 for the treatment of patients with cancer who are receiving myelosuppressive chemotherapy. It was subsequently approved for multiple oncology related indications and severe chronic neutropenia. Multiple filgrastim biosimilars have been approved in the United States, Europe, and elsewhere since 2008.
The retrospective, postmarketing study comprised data from 1991 to May 2018 from VigiBase, a World Health Organization database of adverse events information. VigiBase is often used to aid postmarket studies.
Distribution of Adverse Events
Investigators identified 11,183 adverse drug reaction reports, of which 51.5% (5764) were related to Neupogen, the originator. Leucostim had 680; Zarzio, 622; Grasin, 545; Nivestim, 359; and Tevagrastim, 152.
Grasin was associated with higher reporting of pyrexia, or fever, compared with neupogen (11.5% vs 7.9%, reporting odds ratio [ROR] 1.52); myalgia, or muscle pain, (37% vs 2.2%, ROR 25.94); and back pain (11.3% vs 4%, ROR 3.09).
Findings showed that Zarzio was associated with increased reporting of arthralgia, also known as joint pain (4.5% vs 2.9%, ROR 1.59). Zarzio also had higher reporting of neutropenia, or low white blood cell count (11.4% vs 4%, ROR 2.59).
Bone pain was reported more often for Nivestim than reference filgrastim (14.4% vs 8.3%, ROR 1.87).
Drug ineffectiveness was reported in cases with Zarzio (35.9%), Nivestim (19.4%), and Tevagrastim (42.2%).
Efficacy Differences Also Observed
The authors also observed significant differences between the originator and biosimilars in regard to efficacy, adverse events reported, and time to onset of occurrences.
They stressed that epidemiologic studies are needed to confirm these findings and provide additional insights.
Zarzio is owned by Sandoz and is marketed is as Zarxio in the United States. Grasin is owned by Teva Pharmaceuticals Japan and is marketed in Republic of Korea. Tevagrastim is marketed in Europe and is owned by Teva Generics GmbH, a Teva Pharmaceuticals company. Tevagrastim is marketed as Tbo-filgrastim in the United States. Nivestim is owned by Pfizer and is marketed as Nivestym in the United States.
Leucostim is marketed in Peru, the Republic of Korea, and Turkey.
In the United States, the FDA recently launched the FDA adverse Event Reporting system (FAERS). FAERS is a public search engine for drugs and biologics and contains adverse event reports submitted by healthcare providers, consumers, manufacturers of drugs and biologics, and other stakeholders.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
No Differences in Long-Term Drug Survival Between Biosimilar, Originator TNF Inhibitors
August 15th 2024An analysis of subcutaneous biosimilar and originator tumor necrosis factor (TNF) inhibitors for rheumatic diseases found no significant differences in survival or discontinuation rates due to inefficacy or adverse events, with biosimilars showing lower overall discontinuation rates and higher retention rates.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Indian Providers Boast Interchangeability for Insulin Biosimilars Despite Debates in the US
August 5th 2024The introduction of biosimilar insulins, particularly insulin glargine, is crucial for improving insulin accessibility and adherence among patients with diabetes in India, according to a study evaluating expert opinions from Indian doctors.